PriceTargets.com logo

Tabula Rasa HealthCare - TRHC Stock Price Target and Predictions

  • Consensus Rating: Moderate Buy
  • Consensus Price Target: $10.00
  • Forecasted Upside: -4.76%
  • Number of Analysts: 4
  • Breakdown:
  • 0 Sell Ratings
  • 2 Hold Ratings
  • 2 Buy Ratings
  • 0 Strong Buy Ratings
$10.50 As of 11/3/2023 01:00 AM ET
+0 (0.00%)
Get New Tabula Rasa HealthCare Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for TRHC and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for TRHC

Analyst Price Target is $10.00
▼ -4.76% Downside Potential
This price target is based on 4 analysts offering 12 month price targets for Tabula Rasa HealthCare in the last 3 months. The average price target is $10.00, with a high forecast of $10.00 and a low forecast of $10.00. The average price target represents a -4.76% upside from the last price of $10.50.

This chart shows the closing price for TRHC for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Moderate Buy

The current consensus among 4 contributing investment analysts is to moderate buy stock in Tabula Rasa HealthCare. This Moderate Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 2 buy ratings
  • 2 hold ratings
  • 0 sell ratings
Ratings as of
11/2/2022
  • 0 strong buy ratings
  • 2 buy ratings
  • 2 hold ratings
  • 0 sell ratings
Ratings as of
1/31/2023
  • 0 strong buy ratings
  • 2 buy ratings
  • 2 hold ratings
  • 0 sell ratings
Ratings as of
5/1/2023
  • 0 strong buy ratings
  • 2 buy ratings
  • 2 hold ratings
  • 0 sell ratings
Ratings as of
7/30/2023
  • 0 strong buy ratings
  • 2 buy ratings
  • 2 hold ratings
  • 0 sell ratings
Ratings as of
10/28/2023
  • 0 strong buy ratings
  • 2 buy ratings
  • 2 hold ratings
  • 0 sell ratings
Ratings as of
1/26/2024
  • 0 strong buy ratings
  • 2 buy ratings
  • 2 hold ratings
  • 0 sell ratings
Ratings as of
3/26/2024
  • 0 strong buy ratings
  • 2 buy ratings
  • 2 hold ratings
  • 0 sell ratings
Ratings as of
4/25/2024

Latest Recommendations

  • 0 strong buy ratings
  • 2 buy ratings
  • 2 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
8/7/2023BenchmarkDowngradeBuy ➝ HoldLow
8/7/2023William BlairDowngradeOutperform ➝ Market PerformLow
5/10/2023SVB LeerinkUpgradeMarket Perform ➝ OutperformLow
5/10/2023SVB SecuritiesUpgradeMarket Perform ➝ Outperform$7.00 ➝ $10.00Low
3/10/2023Piper SandlerBoost Target$4.00 ➝ $6.00Low
11/7/2022Piper SandlerLower TargetNeutral$6.00 ➝ $4.00Low
8/18/2022Piper SandlerBoost TargetNeutral$6.00Low
8/8/2022SVB LeerinkBoost TargetMarket Perform$4.00 ➝ $5.50Low
6/22/2022Stifel NicolausLower TargetHold ➝ Hold$5.00Low
3/2/2022BenchmarkLower TargetBuy$30.00 ➝ $15.00Medium
2/28/2022SVB LeerinkLower TargetMarket Perform$23.00 ➝ $11.00High
2/1/2022Robert W. BairdDowngradeOutperform ➝ Neutral$24.00 ➝ $11.00Low
12/1/2021Jefferies Financial GroupInitiated CoverageHold$13.00High
11/9/2021BenchmarkLower TargetBuy$55.00 ➝ $30.00Low
11/8/2021Royal Bank of CanadaLower TargetMarket Perform ➝ Outperform$70.00 ➝ $23.00High
11/8/2021SVB LeerinkLower TargetMarket Perform$40.00 ➝ $23.00High
11/5/2021Piper SandlerLower TargetNeutral$41.00 ➝ $13.00High
11/5/2021Stifel NicolausLower TargetHold$42.00 ➝ $24.00High
9/24/2021SVB LeerinkLower TargetMarket Perform$49.00 ➝ $40.00Medium
7/12/2021Royal Bank of CanadaSet Target$48.26Low
7/11/2021Royal Bank of CanadaReiterated RatingBuyLow
5/27/2021Robert W. BairdInitiated CoverageOutperform$53.00High
5/10/2021SVB LeerinkBoost TargetMarket Perform$43.00 ➝ $49.00High
5/7/2021Piper SandlerBoost TargetNeutral$41.00 ➝ $45.00Low
3/2/2021Cantor FitzgeraldReiterated RatingOverweight ➝ Neutral$40.00Medium
3/2/2021Piper SandlerReiterated RatingOverweight ➝ Neutral$40.00 ➝ $41.00Medium
3/1/2021Truist FinancialDowngradeBuy ➝ Hold$41.00 ➝ $42.00Low
2/25/2021SVB LeerinkLower TargetMarket Perform$47.00 ➝ $43.00High
2/24/2021Piper SandlerDowngradeOverweight ➝ Neutral$40.00 ➝ $41.00High
2/24/2021Cantor FitzgeraldDowngradeOverweight ➝ Neutral$40.00Low
2/2/2021Royal Bank of CanadaBoost TargetOutperform$54.00 ➝ $70.00Low
1/15/2021Stifel NicolausDowngradeBuy ➝ Hold$52.00High
11/5/2020Truist FinancialLower Target$61.00 ➝ $41.00Medium
11/4/2020Piper SandlerLower TargetOverweight$59.00 ➝ $40.00High
11/4/2020SVB LeerinkDowngradeOutperform ➝ Market Perform$56.00 ➝ $38.00High
11/4/2020BenchmarkLower TargetBuy$65.00 ➝ $55.00High
9/23/2020Royal Bank of CanadaReiterated RatingBuy$57.00Low
8/12/2020Truist FinancialLower Target$72.00 ➝ $61.00Low
8/6/2020Wells Fargo & CompanyLower TargetEqual Weight$53.00 ➝ $46.00Medium
8/6/2020Piper SandlerLower TargetOverweight$68.00 ➝ $59.00Medium
8/6/2020SVB LeerinkLower TargetOutperform$65.00 ➝ $56.00Medium
8/5/2020BenchmarkLower TargetBuy$84.00 ➝ $75.00High
7/2/2020SunTrust BanksInitiated CoverageBuy$72.00High
6/25/2020Cantor FitzgeraldLower TargetPositive ➝ Overweight$85.00 ➝ $83.00Low
5/11/2020BenchmarkLower TargetBuy$90.00 ➝ $84.00Low
4/20/2020Royal Bank of CanadaInitiated CoverageOutperform$70.00Medium
4/13/2020SVB LeerinkInitiated CoverageOutperform$65.00High
2/28/2020Wells Fargo & CompanyReiterated RatingHoldHigh
2/28/2020Piper SandlerBoost Target$66.00 ➝ $72.00Low
2/14/2020OppenheimerInitiated CoverageBuy$78.00Low
1/17/2020William BlairReiterated RatingOutperformLow
1/8/2020Wells Fargo & CompanyLower TargetEqual Weight$55.00 ➝ $50.00Low
11/8/2019Cantor FitzgeraldLower TargetOverweight$99.00 ➝ $85.00High
11/8/2019Piper Sandler CompaniesLower TargetOverweight$78.00 ➝ $66.00High
10/18/2019Piper Sandler CompaniesSet TargetBuy$78.00N/A
8/30/2019Stifel NicolausUpgradeHold ➝ Buy$50.00 ➝ $75.00High
5/13/2019Cantor FitzgeraldReiterated RatingBuy$99.00High
5/9/2019Piper Sandler CompaniesBoost TargetOverweight$73.00 ➝ $78.00High
(Data available from 4/25/2019 forward)

News Sentiment Rating

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 2 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
9/28/2023
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
10/28/2023
  • 1 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
11/27/2023
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
12/27/2023
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
1/26/2024
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
2/25/2024
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
3/26/2024
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
4/25/2024

Current Sentiment

  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Positive

  • No positive mentions tracked during this time.

Very Positive

  • No very positive mentions tracked during this time.
Tabula Rasa HealthCare logo
Tabula Rasa HealthCare, Inc. operates as a healthcare technology company in the United States. The company operates in two segments, CareVention HealthCare and MedWise HealthCare. It offers EireneRx, a cloud-based medication decision-support and e-prescribing platform to access patient medication-related information; and MedWise Risk Score, a medication risk stratification technology for identification of patients in need of clinical intervention. The company also provides TruChart that offers electronic health records (EHR), care coordination, and financial management in one program allowing Programs of All-Inclusive Care for the Elderly (PACE) to track measurable outcomes in defined timeframes for the populations they serve; and PACElogic, which delivers sharable workflows comprising EHR, customer relationship management, claims adjudication, electronic data interchange, care management, coordination and planning, integration with community-based providers, and various federal and state that requires reporting. In addition, it provides clinical pharmacist collaboration, prescription fulfillment and adherence packaging, and pharmacy benefit management services, as well as health plan management services, including risk adjustment and third-party administrator services. As of December 31, 2022, it served approximately 150 healthcare organizations. The company provides cloud-based software applications to assist prescribers and pharmacists. Tabula Rasa HealthCare, Inc. was founded in 2009 and is headquartered in Moorestown, New Jersey. As of November 3, 2023, Tabula Rasa HealthCare, Inc. operates as a subsidiary of Exact Care Pharmacy, LLC.
Read More

Today's Range

Now: $10.50
Low: $10.50
High: $10.50

50 Day Range

MA: $10.45
Low: $10.37
High: $10.50

52 Week Range

Now: $10.50
Low: $3.15
High: $10.50

Volume

N/A

Average Volume

225,500 shs

Market Capitalization

$284.13 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.57

Frequently Asked Questions

What sell-side analysts currently cover shares of Tabula Rasa HealthCare?

The following Wall Street research analysts have issued stock ratings on Tabula Rasa HealthCare in the last twelve months: Benchmark Co., StockNews.com, SVB Leerink LLC, SVB Securities, and William Blair.
View the latest analyst ratings for TRHC.

What is the current price target for Tabula Rasa HealthCare?

1 Wall Street analysts have set twelve-month price targets for Tabula Rasa HealthCare in the last year. Their average twelve-month price target is $10.00, suggesting a possible downside of 4.8%. SVB Securities has the highest price target set, predicting TRHC will reach $10.00 in the next twelve months. SVB Securities has the lowest price target set, forecasting a price of $10.00 for Tabula Rasa HealthCare in the next year.
View the latest price targets for TRHC.

What is the current consensus analyst rating for Tabula Rasa HealthCare?

Tabula Rasa HealthCare currently has 2 hold ratings and 2 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Moderate Buy."
View the latest ratings for TRHC.

What other companies compete with Tabula Rasa HealthCare?

Other companies that are similar to Tabula Rasa HealthCare include Forian, ESSA Pharma, Akebia Therapeutics, Sanara MedTech and Sight Sciences. Learn More about companies similar to Tabula Rasa HealthCare.

How do I contact Tabula Rasa HealthCare's investor relations team?

Tabula Rasa HealthCare's physical mailing address is 228 STRAWBRIDGE DRIVE SUITE 100, MOORESTOWN NJ, 08057. The company's listed phone number is (866) 648-2767 and its investor relations email address is [email protected]. The official website for Tabula Rasa HealthCare is www.tabularasahealthcare.com. Learn More about contacing Tabula Rasa HealthCare investor relations.